# Pediatric MASLD in Severe Obesity: Current Clinical Perspectives on Diagnosis and Treatment

## TL;DR

This paper reviews the diagnosis and treatment of liver disease in children with severe obesity, emphasizing early screening and lifestyle changes.

## Contribution

The paper proposes practical screening algorithms and highlights the need for improved non-invasive biomarkers in pediatric MASLD.

## Key findings

- Screening with ALT is recommended for children aged 9–11 with obesity or additional risk factors.
- Lifestyle modification is the primary treatment, while bariatric surgery is effective for adolescents with severe obesity.
- Non-invasive imaging has limitations in children with high subcutaneous fat.

## Abstract

Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) is now one of the most common chronic liver diseases in children and closely parallels the rising prevalence of severe pediatric obesity. Methods: This review synthesizes current evidence (2019–2025) and landmark studies on the diagnosis and management of pediatric MASLD, integrating contemporary guidelines and future directions. Results: Based on current data, we propose practical algorithms for screening and management of pediatric MASLD. Screening with alanine aminotransferase (ALT) as the initial test should be initiated in all children aged 9–11 years with obesity, in those who are overweight with additional risk factors, and in children with severe obesity or a family history of MASLD. Non-invasive imaging techniques show important limitations in children with increased amount of subcutaneous tissue requiring cautious interpretation. Lifestyle modification remains the cornerstone of therapy, while pharmacological treatments are investigational. In adolescents with severe obesity and significant comorbidities, bariatric surgery represents an effective therapeutic option with durable metabolic effects. Conclusions: Early identification of high-risk children, especially those with severe obesity, and implementation of multidisciplinary management are essential to prevent MASLD progression. Refinement of screening strategies and development of validated non-invasive biomarkers remain key priorities for future pediatric care.